Cyrus Poonawalla on Scale Economics

Poonawalla founded the Serum Institute of India in 1966 and built it into the world's largest vaccine manufacturer by volume, supplying over 140 countries. Wikipedia notes the company produces more than 1.5 billion doses annually of vaccines for measles, polio and the flu. The scale of this single private company is what later enabled India to anchor the global COVID-19 vaccination response.

In 2022, Poonawalla was ranked the 4th richest person in India on the Forbes India rich list with a net worth of $24.3 billion, and was ranked number 1 on the Hurun Global Healthcare Rich List 2022. By October 2024, Forbes listed Poonawalla and his family as the ninth-wealthiest in India with a net worth of $22.1 billion. The wealth trajectory — driven by COVID-era vaccine scale — places him as one of India's richest promoters.

Poonawalla owns a pair of Bombardier Global 6500 luxury jets (range 6,500 nautical miles, top speed Mach 0.90, about 690mph), having switched from two Gulfstreams because his son Adar preferred the Global. The personal detail signals the scale of private wealth the vaccine business has produced —.

Poonawalla and his younger brother Zavaray established Serums Institute of India in 1966 with starting capital of about US$25,000, growing from serums (which had limited use) into vaccines for diphtheria, tetanus, whooping cough, pneumonia, measles, and eventually the COVID vaccines Covovax and Covishield.

Poonawalla describes the COVID business windfall starkly: before COVID in 2019 he was India's 12th richest person (world rank 76th, fortune US$9.1 billion); by end-2022 he was India's fourth-richest, fortune expanded to US$21.5 billion and climbing — US$22.4 billion at the time of the interview. He frames Serum as one of the largest competitors to Pfizer and the world's biggest vaccine producer by number produced and sold.

Poonawalla explicitly positions himself as a philanthropist throughout: 'our price is low, I've been giving vaccines at 50 cents a dose and nobody could compete with this'. Serum was pre-qualified by WHO and the UK's MHRA, on which basis the company could make three billion doses of vaccine, including substantial COVID production.

Poonawalla cites recent export milestones: just that week Serum had exported six million COVID doses to Australia and three million to New Zealand, with an American-subidiary contract to supply 100 million doses to those two markets and roughly two billion doses worldwide at peak pandemic. The numbers demonstrate how a private Indian company became a top-tier global public-health supplier —.

NPR opens by noting the Poonawallas — Cyrus as founder and Adar as CEO of Serum Institute — run the world's largest vaccine-producing company in the world's largest vaccine-producing nation. Serum makes vaccines for measles, tetanus, diphtheria, hepatitis and many other diseases, specializes in generic versions, exports to 170 countries, and estimates that two-thirds of the world's children are inoculated with its vaccines.

Inside Serum's sprawling Pune factory, NPR describes filled vaccine vials whizzing off conveyor belts at around 5,000 per minute. Scientists in goggles and gloves steered microscopes over a chimpanzee virus spiked with coronavirus protein. Human embryonic kidney cells fermented in floor-to-ceiling stainless steel vats imported from Europe that cost upward of $4 million each.

NPR notes Serum has partnered with the Bill & Melinda Gates Foundation and several United Nations agencies including UNICEF and the World Health Organization. By the time of the report, the company said it would ramp Oxford-AstraZeneca vaccine production to 100 million doses per month by April 2021.

NPR records that by December 2020, when governments worldwide began granting emergency authorization, Serum already had hundreds of millions of doses ready to ship. The company promised half its production to the Indian government, which donated and sold supplies to about 70 countries. Serum was producing 60-70 million Oxford-AstraZeneca doses — branded as COVISHIELD —.

NPR notes a January 2021 electrical fire at Serum's Pune complex killed five people, though vaccine production was not affected. The image of black smoke billowing from the complex where Indians' best hope for COVID salvation was being produced was frightening for a watching nation. The episode illustrates how, at peak scale, operational risk at a single facility can become a national-public-health concern.